| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Investments | NaN | NaN | 3,581,772 | 6,121,830 |
| Cash and cash equivalents | 3,124,523 | 3,818,096 | 1,830,906 | 1,668,492 |
| Investments | 10,918,778 | 14,927,165 | NaN | NaN |
| Prepaid expenses and other current assets | 1,291,256 | 1,261,974 | 602,652 | 688,933 |
| Total current assets | 15,334,557 | 20,007,235 | 6,015,330 | 8,479,255 |
| Intangible assets, net | 358,334 | 383,334 | 408,334 | 433,334 |
| Total assets | 15,692,891 | 20,390,569 | 6,423,664 | 8,912,589 |
| Accrued interest and financing expense | NaN | NaN | 1,146,251 | 1,146,251 |
| Accounts payable | 1,776,231 | 1,262,222 | 1,860,719 | 873,684 |
| Accrued expenses | 1,823,544 | 2,538,457 | 2,157,581 | 1,717,564 |
| Accrued interest and financing expense | 1,146,251 | 1,146,251 | NaN | NaN |
| Due to officers - short term | 600,000 | 600,000 | 600,000 | 600,000 |
| Total current liabilities | 5,346,026 | 5,546,930 | 5,764,551 | 4,337,499 |
| Due to officers - long term | 1,573,733 | 1,723,733 | 1,873,733 | 2,023,733 |
| Total liabilities | 6,919,759 | 7,270,663 | 7,638,284 | 6,361,232 |
| Ordinary shares, no par value per share, 5,000,000,000 authorized at march 31, 2026 and december 31, 2025, respectively - 68,642,195 (1,961,206 ads's) ordinary shares issued and outstanding at march 31, 2026 and 52,441,360 (1,498,325 ads's) ordinary shares issued and outstanding at december 31, 2025 | 0 | 0 | 0 | 0 |
| Accumulated other comprehensive loss | -159 | -613 | NaN | NaN |
| Additional paid in capital | 84,741,473 | 84,090,966 | 65,407,454 | 65,225,266 |
| Accumulated deficit | -75,968,182 | -70,970,447 | -66,622,074 | -62,673,909 |
| Total shareholders' equity | 8,773,132 | 13,119,906 | -1,214,620 | 2,551,357 |
| Total liabilities and shareholders' equity | 15,692,891 | 20,390,569 | 6,423,664 | 8,912,589 |
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)